This is the form of material change report required under Section 85(1) of the Securities Act.

BC FORM 51-102F3
(formerly Form 53-901F)

Securities Act

MATERIAL CHANGE REPORT UNDER SECTION 85(1) OF THE ACT

Item 1. Reporting Issuer

Trigen Resources Inc.
Suite2050 – 1055 West Georgia Street
PO Box 11121, Royal Centre
Vancouver, BC V6E 3P3

Item 2. Date of Material Change

February 19, 2018

Item 3. Press Release

February 19, 2018, at Vancouver, BC, Canada.

Item 4. Summary of Material Change

Trigen Resources Inc announces that the common shares of the Company will be voluntarily delisted from the TSXV effectively at the close of market February 21st, 2018.

Item 5. Full Description of Material Change

See attached press release.

Item 6. Reliance on Section 85(2) of the Act

N/A

Item 7. Omitted Information

None

Item 8. Senior Officers

The following senior officers of the Issuer are knowledgeable about the material change and may be contacted by the Commission at the address and telephone number:

Hari Varshney President, CEO & Director (604) 684-2181	Praveen Varshney Director (604) 684-2181

Item 9. **Statement of Senior Officer**

The foregoing accurately discloses the material change referred to herein.

Dated this 19th day of February, 2018

"Praveen Varshney"

Praveen Varshney
Name

Director
Position / Title

Vancouver, B.C.
Place of Declaration

TRIGEN RESOURCES INC.

NEWS RELEASE
TSXV: TRG.H

Not for distribution in the U.S. or to U.S. newswire services.

TRIGEN SEEKING VOLUNTARY DELISTNG FROM TSXV TO COMPLETE TRANSACTION WITH BLISSCO

Vancouver, British Columbia – Monday, February 19, 2018 **-** Trigen Resources Inc. ("Trigen" or the "Company") announces that the common shares of the Company will be voluntarily delisted from the TSXV effectively at the close of market February 21st, 2018.

Trigen has voluntarily delisted from the TSXV in order to complete the Bliss Co Holdings Ltd. ("Blissco") acquisition and related $5,500,000 concurrent financing as disclosed in the news releases dated September 18, 2017, November 7, 2017 and January 25, 2018. The closing of the acquisition and the related financing are conditions for the listing on the Canadian Securities Exchange ("CSE").

The Company has received confirmation that the CSE has granted conditional approval for listing.

About BlissCo

BlissCo is constructing an urban Access to Cannabis for Medical Purposes Regulation (ACMPR) cultivation facility with a focus on being a high-volume packager, processor and distributor of recreational cannabis when it is legal in Canada, which is currently anticipated to be by July 2018, and of medical cannabis. It recently took ownership of its 12,600 sq. ft. industrial facility in Langley, British Columbia and considering the May 2017 changes Health Canada announced to the licensing process BlissCo is confident that its license will be earned shortly after completing construction.

With an ACMPR cultivation and then a sales license BlissCo will grow and sell dried cannabis and cannabis oil to approved medical patients through its online portal and service excellence call centre. BlissCo will focus on high volume sales opportunities in the legal cannabis market when individual distribution models are established by Canadian provinces and territories.

The common shares of the Company are currently halted and will remain halted pending completion of the Proposed Transaction.

ON BEHALF OF THE BOARD of DIRECTORS

TRIGEN RESOURCES INC.

"Praveen Varshney"
Praveen Varshney, FCPA, FCA,
Director

For further information please contact:
Karan Thakur
778.987.3446
Kthakur.vcc@gmail.com

Cautionary Statement

Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Trigen should be considered highly speculative. There can be no assurance that Health Canada will issue a license to BlissCo in the time stated, or at all, or on terms that BlissCo will find acceptable.

The TSX Venture Exchange Inc. and CSE have in no way passed upon the merits of the proposed transaction and have neither approved nor disapproved the contents of this press release.